| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND: There is scarce data regarding the use of Remdesivir in Severe acute respiratory distress syndrome Corona virus 2 (SARS CoV2) patients with End Stage Renal Disease (ESRD) as the Food and Drug Administration (FDA) cautions against its use in patients with estimated glomerular filtration rate(eGFR) less than 30ml/min/1.73m(2) unless the potential benefits outweigh potential risks. We intend to study the compassionate use and safety profile of remdesivir in End stage renal disease patients with moderate to severe SARS CoV2 infection. METHODS: We conducted an observational prospective study in 48 dialysis dependent patients with SARS CoV2 infection who received remdesivir as part of institutional treatment protocol. During the treatment period, 100 mg of remdesivir was given 4 hours before hemodialysis sessions. Liver function tests (LFT), Inflammatory markers such as serum C-reactive protein (CRP), ferritin, Lactate dehydrogenase (LDH) levels, oxygen requirement before and after remdesivir treatment were compared. RESULTS: There were no events of significant LFT alteration with administration of 2-6 doses of remdesivir. Significant decline in Serum CRP level (p<0.001) was noted. 68.57% of patients showed an improvement in oxygen requirement. Early administration of remdesivir within 48 hours of hospital admission shortened the duration of hospitalization by mean of 5.5 days(p=0.001) CONCLUSION: Remdesivir was well tolerated and found safe in our study. If initiated within 48 hours of hospitalisation, it reduces recovery time. It requires further randomized control trial with larger population to assess mortality benefits.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
-
10.1016/j.ekir.2020.12.003
|
|
?:doi
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/6a4aeee5e738f2eb1341ae85648386e32cedad6f.json
|
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7746511.xml.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
USE OF REMDESIVIR IN PATIENTS WITH COVID-19 ON HEMODIALYSIS- A STUDY OF SAFETY AND TOLERANCE
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}